Earnings call transcript: Teva Q1 2026 earnings beat forecasts

Teva reported Q1 2026 EPS of $0.53 versus $0.48 expected and revenue of $4.0 billion versus $3.81 billion, while free cash flow rose 76% year over year to about $200 million. Innovative products drove growth, with Austedo up 41%, UZEDY up 62%, and AJOVY up 35%, supporting reaffirmed 2026 guidance and a pre-market stock gain of 10.91% to $35.07. The company also announced a $700 million cash acquisition of Amylyx, adding an orphan CNS asset with potential 2027 launch and reinforcing the Pivot to Growth strategy.

Analysis

TEVA’s print matters less for the headline beat than for what it says about the earnings mix: the market is re-rating this as a durability story, not a one-quarter event. The important second-order effect is that innovative-product momentum is now funding a more aggressive capital-allocation regime — the buyback signal plus the AMLX deal means management is explicitly trying to convert incremental cash flow into multiple expansion, not just debt reduction. That should keep the stock supported on pullbacks as long as payers don’t choke off the growth franchises.

The real swing factor is the bridge between now and the 2027 margin target. Near-term, the biggest risk is not the pipeline; it is channel normalization and IRA-related pre-buy behavior around Austedo, which can create a deceptively strong/weak sequence over the next 2-3 quarters. If the channel remains elevated longer than expected, reported growth can decelerate while underlying prescription momentum stays intact — a setup that often punishes holders who anchor on reported revenue rather than TRx/mg trends.

AMLX is strategically clever but financially nuanced: TEVA is buying a late-stage CNS asset with orphan-like economics, yet the market will likely underappreciate the lag between upfront dilution and launch-era accretion. That creates a window where the stock may overreact to the 2026 EPS hit even though the transaction actually increases the probability of sustained CNS franchise leverage into 2028-2030. The contrarian read is that consensus may be too focused on the dilution math and not enough on the optionality from a high-margin rare-disease launch platform plus a likely buyback on a cleaner balance sheet.

Watch for two reversal catalysts: a softer-than-expected Austedo channel read through Q2/Q3, or any regulatory/trial noise on the new CNS assets that forces investors to re-apply a biotech discount. Conversely, if management proves the 2027 leverage target is intact while continuing to lift innovative mix, the stock can keep rerating even without upward guidance revisions.

Key Decisions for Investors

• Long TEVA on 1-3 month pullbacks; target a re-rating toward higher-teens FCF multiple if Austedo/TRx stays firm and buyback timing is confirmed. Stop on any evidence that reported growth is rolling over faster than underlying scripts.
• Buy TEVA Jan-2027 / Jan-2028 call spreads to express the view that 2026 EPS dilution from AMLX is a setup for 2027-2028 accretion. Risk/reward is favorable if the market underprices the launch ramp.
• Pair trade: long TEVA vs short a basket of slower-growth generic pharma peers over the next 6-12 months. TEVA’s mix shift and capital returns should drive multiple expansion relative to businesses still dependent on low-margin legacy generics.
• Use any post-earnings strength to sell near-dated covered calls against a TEVA long if you already own the name; the near-term path likely remains choppy around channel and IRA headlines, but downside should be cushioned by cash flow and buyback support.
• Avoid overexposure to AMLX standalone until the takeout closes; the cleaner expression is TEVA, where you get the acquisition optionality without binary deal-close risk.